Literature DB >> 16298124

Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma.

Laura Boldrini1, Silvia Gisfredi, Silvia Ursino, Pinuccia Faviana, Marco Lucchi, Franca Melfi, Alfredo Mussi, Fulvio Basolo, Gabriella Fontanini.   

Abstract

The endothelin (ET) system influences tumourigenesis and tumour progression by various mechanisms, including angiogenesis. The aim of this study was to determine whether the expression of endothelin-1 (ET-1) is related to the angiogenic phenomenon in lung cancer and whether it could be involved in its clinical behaviour. Expression of ET-1, endothelin-converting enzyme-1 (ECE-1) and endothelin-receptors ETA and ETB was examined in 201 non-small cell lung carcinoma (NSCLC) and corresponding normal tissues using real-time polymerase chain reaction (RT-PCR). Forty NSCLC were also analysed for vascular endothelial growth factor (VEGF) expression by a competitive-PCR approach to assess whether ET-1 expression was related to this angiogenic factor. A higher number of cases with ET-1, ECE-1 and ETA mRNA expression was observed in malignant lung tumours compared with normal lung tissues (45.7% versus 33% for ET-1 (P < 0.0001); 38.3% versus 16.5% for ECE-1 (P = 0.004); and 42.8% versus 28.5% for ETA (P < 0.0001)). On the other hand, ETB mRNA was higher in normal lung tissues than in tumour samples (58.5% versus 52.8% (P < 0.0001)). Immunohistochemical analysis was also performed in 78 cases, selected from among those with high ET-1 mRNA, to confirm the presence of ET-1 protein and to determine its distribution and localisation. Moreover, an interesting relationship was observed between ET-1 and VEGF mRNA levels (P = 0.02). At univariate analysis, clinical-pathological parameters, such as sex, nodal metastatic involvement and stage, and ET-1 expression were seen to be significant predictors of worse prognosis regarding both overall survival (P = 0.001, P = 0.0003, P = 0.001 and P = 0.03, respectively) and disease-free interval (P = 0.0005, P = 0.0007, P = 0.001 and P = 0.04, respectively). We conclude that ET-1 could be involved in angiogenic phenomena in NSCLC and may represent a further indicator of progression and poor prognosis in this type of cancer, with interesting therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16298124     DOI: 10.1016/j.ejca.2005.08.030

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  12 in total

1.  Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Paula Moreno; Samuel A Mantey; Lisa Ridnour; David Wink; Robert T Jensen
Journal:  Peptides       Date:  2017-01-31       Impact factor: 3.750

2.  Expression of endothelin 1 and its angiogenic role in meningiomas.

Authors:  Laura Boldrini; Sabina Pistolesi; Silvia Gisfredi; Silvia Ursino; Greta Alì; Nicola Pieracci; Fulvio Basolo; Giuliano Parenti; Gabriella Fontanini
Journal:  Virchows Arch       Date:  2006-09-30       Impact factor: 4.064

Review 3.  Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Authors:  Laura Rosanò; Francesca Spinella; Anna Bagnato
Journal:  Nat Rev Cancer       Date:  2013-07-25       Impact factor: 60.716

4.  Large-scale analysis of network bistability for human cancers.

Authors:  Tetsuya Shiraishi; Shinako Matsuyama; Hiroaki Kitano
Journal:  PLoS Comput Biol       Date:  2010-07-08       Impact factor: 4.475

5.  Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

Authors:  Inés Pulido; Stephen Ollosi; Salvador Aparisi; Jeffrey H Becker; Alicia Aliena-Valero; Marta Benet; María L Rodríguez; Adrián López; Eva Tamayo-Torres; Lourdes Chuliá-Peris; Juan Carlos García-Cañaveras; Margaret Soucheray; Annika V Dalheim; Juan B Salom; Wei Qiu; Simon Kaja; Javier Alcácer Fernández-Coronado; Sandra Alandes; Javier Alcácer; Fátima Al-Shahrour; Jeffrey A Borgia; Oscar Juan; Michael I Nishimura; Agustín Lahoz; Julián Carretero; Takeshi Shimamura
Journal:  Cancer Res       Date:  2020-08-03       Impact factor: 12.701

6.  Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

Authors:  Ho Jeong Lee; Masaki Hanibuchi; Sun-Jin Kim; Hyunkyung Yu; Mark Seungwook Kim; Junqin He; Robert R Langley; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neuro Oncol       Date:  2016-04       Impact factor: 12.300

7.  Effect of endothelin-1 in esophageal squamous cell carcinoma invasion and its correlation with cathepsin B.

Authors:  Wen-Jie Jiao; Jing Xu; Hao Pan; Tian-You Wang; Yi Shen
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

Review 8.  Hypoxia, angiogenesis, and lung cancer.

Authors:  Ranjit K Goudar; Gordana Vlahovic
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

9.  Role of endothelin receptor signalling in squamous cell carcinoma.

Authors:  Shunsuke Ishimoto; Koichiro Wada; Noriaki Tanaka; Tadashi Yamanishi; Kohji Ishihama; Tomonao Aikawa; Masaya Okura; Atsushi Nakajima; Mikihiko Kogo; Yoshinori Kamisaki
Journal:  Int J Oncol       Date:  2011-11-10       Impact factor: 5.650

10.  Elevation of circulating big endothelin-1: an independent prognostic factor for tumor recurrence and survival in patients with esophageal squamous cell carcinoma.

Authors:  Wenjie Jiao; Jing Xu; Jinsheng Zheng; Yi Shen; Lesheng Lin; Jian Li
Journal:  BMC Cancer       Date:  2008-11-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.